XenoGesis has been identified as ‘one to watch’ in Alantra’s Pharma Fast 50 which was published in the Pharma Times this month.
Alantra’s annual report on the fastest-growing pharma companies and lists those businesses that have increased their revenues at the fastest rate over the past two financial years. As XenoGesis does not file audited accounts, it could not be included in this year’s rankings, but has been recognised by Alantra for its outstanding growth rates and identified as an emerging contender for the Fast 50.
CEO and Founder, Dr Richard Weaver, said: “We are delighted to have been identified as one to watch. XenoGesis is on an exciting growth trajectory, as we attract biotechs that are looking for teams of specialists who do more than just what they’re told as well as helping avoid dead ends and increasing the speed to market.”
Based at BioCity Nottingham, XenoGesis specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology, DMPK due diligence and modelling and simulation, and has worked directly on the predictions of human PK and dose for seven compounds that have entered clinic. Founded in 2011 by Dr Richard Weaver, the company has grown from three to over 30 members of staff, investing in state-of-the-art instrumentation and facilities. Revenue has grown year on year, with a significant growth in exports as the company expands its client base overseas.
To read the article and see this year’s listing in the March edition of Pharma Times, click here.